Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.40), in-line with the analyst estimate of ($0.40).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Darden Restaurants stock slips premarket despite Q4 earnings beat
• Jefferies Group (JEF) PT Lowered to $83 at Oppenheimer